JMJD2A antibody was raised against a 14 amino acid peptide from near the center of human JMJD2A.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Target description
Members of the Jumonji domain 2 (JMJD2) family contain a JmjN domain, a JmjC domain, a JD2H domain, two TUDOR domains, and two PHD-type zinc fingers. The first member of this group, JMJD2A, is widely expressed in human tissues and cell lines and functions as a trimethylation-specific demethylase, converting specific trimethylated histone residues to the dimethylated form, and as a transcriptional repressor. JMJD2A can also form a complex with the androgen receptor (AR), a transcription factor that is pivotal for the development of prostate cancer. Overexpression of JMJD2A stimulates AR function and this stimulation is dependent on JMJD2A catalytic activity, suggesting that JMJD2A might be a critical protein with roles in cell proliferation and oncogenesis.
Linkage
The action of this antibody can be blocked using blocking peptide SBP3500095.
Physical form
Supplied at approx. 1 mg/mL in phosphate buffered saline containing 0.02% sodium azide.
International journal of molecular medicine, 37(1), 189-196 (2015-11-05)
The epigenetic modification of vascular smooth muscle cell (VSMC) phenotypic switching, proliferation, migration, apoptosis and extracellular matrix synthesis is known to occur in atherosclerosis. The aim of the present study was to investigate the effects of IOX1, a Jumonji domain-containing
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
